Retinal RPE-Photoreceptor Bilayer Scaffold for Cell Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration and other retinal dysfunctions, such as retinitis pigmentosa and cone-rod dystrophies, are inadequate as they primarily target either retinal pigment epithelium (RPE) or photoreceptor (PR) cells independently, failing to leverage the symbiotic relationship between the two cell types for effective therapy.
Innovation Solution
A bilayer culture therapy comprising photoreceptor precursor cells (PRP) and/or photoreceptor cells (PR) in combination with retinal pigment epithelium cells (RPE) on a biodegradable scaffold, which can be xeno-free and feeder-free, with specific cell types expressing markers like Bestrophin-1 and being polarized, attached via cell-cell contact or a shared matrix, and supported by various biodegradable materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate cell therapies targeting only RPE or only photoreceptors are used, then the treatment approach is simpler and easier to implement, but the therapeutic effectiveness is insufficient because the symbiotic relationship between RPE and photoreceptors is not leveraged
Solution Approach 1:
The patent combines RPE cells and photoreceptor cells into a single bilayer tissue construct, merging two separate cell therapies into one integrated implant. This allows the symbiotic relationship between RPE and photoreceptors to be leveraged for enhanced therapeutic effectiveness while simplifying the delivery process compared to separate transplantation procedures
Solution Approach 2:
The bilayer construct serves multiple functions simultaneously: the RPE layer provides metabolic support and waste removal for photoreceptors, while the photoreceptor layer provides light sensing function. This multi-functionality in a single construct addresses both RPE dysfunction and photoreceptor loss that occur in AMD
2Reliability
If a bilayer construct combining RPE and photoreceptor cells is used, then the therapeutic effectiveness is enhanced by leveraging the symbiotic relationship between cells, but the structural complexity and manufacturing difficulty increase
Solution Approach 1:
The bilayer construct is segmented into distinct RPE and photoreceptor cell layers, each maintaining its specific function and organization. This segmentation allows for specialized culture conditions and quality control for each cell type while preserving the natural architecture required for therapeutic effectiveness
Solution Approach 2:
The patent uses an extracellular matrix scaffold as an intermediary structure to support the bilayer construct during manufacturing and transplantation. This scaffold facilitates the assembly of RPE and photoreceptor cells into the correct architectural configuration and provides structural integrity during handling
3Reliability
If traditional feeder-based cell culture methods are used, then cell growth and maintenance is easier, but the therapy introduces xenogeneic contaminants that reduce safety and purity
Solution Approach 1:
The patent removes feeder cells from the culture system, extracting the xenogeneic component that causes contamination. Instead, the RPE and photoreceptor cells are cultured using feeder-free methods with defined media and extracellular matrix coatings, ensuring xeno-free status and improved safety while maintaining cell viability and function
Data Source
AI summary
Provided herein are methods of producing a distinct bilayer culture of retinal epithelial cells (RPE) with photoreceptor cells and/or photoreceptor precursor cells (PR/PRP). Further provided herein is a therapy comprising transplantation of the RPE and PR/PRP bilayer as well as methods for testing candidate drugs using the bilayer.